The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy
Open accessAbstract
Tumors are composed of abnormally transformed cell types and tissues that differ from normal tissues in their genetic and epigenetic makeup, metabolism, and immunology. Molecular compounds that modulate the immune response against neoplasms offer promising new strategies to combat cancer. Inhibitors targeting the indoleamine-2,3-dioxygenase 1 enzyme (IDO1) represent one of the most potent therapeutic opportunities to inhibit tumor growth. Herein, we assess the biochemical role of IDO1 in tumor metabolism and immune surveillance, and review current diagnostic and therapeutic approaches that are intended to increase the effectiveness of immunotherapies against highly aggressive and difficult-to-treat IDO-expressing cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Liu, Y., Liang, X., Yin, X., Lv, J., Tang, K., Ma, J., Ji, T., Zhang, H., Dong, W., Jin, X., et al. (2017) · Nature Communications · doi:10.1038/ncomms15207 · Cited by 212
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
A subcellular map of the human proteome
Thul, P. J., Åkesson, L., Wiking, M., Mahdessian, D., Geladaki, A., Ait Blal, H., Alm, T., Asplund, A., Björk, L., Breckels, L. M., et al. (2017) · Science · doi:10.1126/science.aal3321 · Cited by 2,813
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I., Conway, S. J., Marshall, B., Brown, C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,585
Chromatin architecture reorganization during stem cell differentiation
Dixon, J. R., Jung, I., Selvaraj, S., Shen, Y., Antosiewicz-Bourget, J. E., Lee, A. Y., Ye, Z., Kim, A., Rajagopal, N., Xie, W., et al. (2015) · Nature · doi:10.1038/nature14222 · Cited by 1,646
CTLA-4–Ig regulates tryptophan catabolism in vivo
Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A., Candeloro, P., Belladonna, M. L., Bianchi, R., Fioretti, M. C., et al. (2002) · Nature Immunology · doi:10.1038/ni846 · Cited by 1,161
Cancer immunoediting from immune surveillance to immune escape
Kim, R., Emi, M., & Tanabe, K. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02587.x · Cited by 1,074
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
Munn, D. H., & Mellor, A. L. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.002 · Cited by 1,041
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
Munn, D. H., & Mellor, A. L. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.001 · Cited by 1,037
Regulation of Immune Responses by mTOR
Powell, J. D., Pollizzi, K. N., Heikamp, E. B., & Horton, M. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075024 · Cited by 836
Aryl hydrocarbon receptor control of a disease tolerance defence pathway
Bessede, A., Gargaro, M., Pallotta, M. T., Matino, D., Servillo, G., Brunacci, C., Bicciato, S., Mazza, E. M. C., Macchiarulo, A., Vacca, C., et al. (2014) · Nature · doi:10.1038/nature13323 · Cited by 674
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
Holmgaard, R. B., Zamarin, D., Li, Y., Gasmi, B., Munn, D. H., Allison, J. P., Merghoub, T., & Wolchok, J. D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.077 · Cited by 482
Adenosine receptors in regulation of dendritic cell differentiation and function
Novitskiy, S. V., Ryzhov, S., Zaynagetdinov, R., Goldstein, A. E., Huang, Y., Tikhomirov, O. Y., Blackburn, M. R., Biaggioni, I., Carbone, D. P., Feoktistov, I., et al. (2008) · Blood · doi:10.1182/blood-2008-02-136325 · Cited by 430
Indoleamine 2,3‐dioxygenase in T‐cell tolerance and tumoral immune escape
Katz, J. B., Muller, A. J., & Prendergast, G. C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00610.x · Cited by 398
Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Godin-Ethier, J., Hanafi, L.-A., Piccirillo, C. A., & Lapointe, R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1331 · Cited by 392
Okamoto, A., Nikaido, T., Ochiai, K., Takakura, S., Saito, M., Aoki, Y., Ishii, N., Yanaihara, N., Yamada, K., Takikawa, O., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2671 · Cited by 390
Cells Expressing Indoleamine 2,3-Dioxygenase Inhibit T Cell Responses
Mellor, A. L., Keskin, D. B., Johnson, T., Chandler, P., & Munn, D. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.8.3771 · Cited by 348
Liu, S. F., Ye, X., & Malik, A. B. (1999) · Circulation · doi:10.1161/01.cir.100.12.1330 · Cited by 346
Mondanelli, G., Bianchi, R., Pallotta, M. T., Orabona, C., Albini, E., Iacono, A., Belladonna, M. L., Vacca, C., Fallarino, F., Macchiarulo, A., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.01.005 · Cited by 333
Trial watch: IDO inhibitors in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A., Sautès-Fridman, C., Tartour, E., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 326
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
Zhai, L., Spranger, S., Binder, D. C., Gritsina, G., Lauing, K. L., Giles, F. J., & Wainwright, D. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0420 · Cited by 322
Löb, S., Königsrainer, A., Zieker, D., Brücher, B. L. D. M., Rammensee, H.-G., Opelz, G., & Terness, P. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0513-6 · Cited by 304
The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
Brochez, L., Chevolet, I., & Kruse, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.011 · Cited by 270
GTRD: a database of transcription factor binding sites identified by ChIP-seq experiments
Yevshin, I., Sharipov, R., Valeev, T., Kel, A., & Kolpakov, F. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw951 · Cited by 246
Tryptophan-Degrading Enzymes in Tumoral Immune Resistance
van Baren, N., & Van den Eynde, B. J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00034 · Cited by 228
Thomas, S. R., Mohr, D., & Stocker, R. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36645-0 · Cited by 212
A Defect in Tryptophan Catabolism Impairs Tolerance in Nonobese Diabetic Mice
Grohmann, U., Fallarino, F., Bianchi, R., Orabona, C., Vacca, C., Fioretti, M. C., & Puccetti, P. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030633 · Cited by 210
Orabona, C., Pallotta, M. T., Volpi, C., Fallarino, F., Vacca, C., Bianchi, R., Belladonna, M. L., Fioretti, M. C., Grohmann, U., & Puccetti, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810278105 · Cited by 204
Zhai, L., Ladomersky, E., Lauing, K. L., Wu, M., Genet, M., Gritsina, G., Győrffy, B., Brastianos, P. K., Binder, D. C., Sosman, J. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0120 · Cited by 177
Hennequart, M., Pilotte, L., Cane, S., Hoffmann, D., Stroobant, V., Plaen, E. D., & Eynde, B. J. V. D. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0400 · Cited by 171
New Insights into IDO Biology in Bacterial and Viral Infections
Schmidt, S. V., & Schultze, J. L. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00384 · Cited by 170
Routy, J.-P., Routy, B., Graziani, G. M., & Mehraj, V. (2016) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s38355 · Cited by 169
Li, Q., Harden, J. L., Anderson, C. D., & Egilmez, N. K. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502615 · Cited by 164
Zhao, Q., Kuang, D.-M., Wu, Y., Xiao, X., Li, X.-F., Li, T.-J., & Zheng, L. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1100164 · Cited by 161
Understanding the role of the kynurenine pathway in human breast cancer immunobiology
Heng, B., Lim, C. K., Lovejoy, D. B., Bessede, A., Gluch, L., & Guillemin, G. J. (2015) · Oncotarget · doi:10.18632/oncotarget.6467 · Cited by 151
IL-27 induces the expression of IDO and PD-L1 in human cancer cells
Carbotti, G., Barisione, G., Airoldi, I., Mezzanzanica, D., Bagnoli, M., Ferrero, S., Petretto, A., Fabbi, M., & Ferrini, S. (2015) · Oncotarget · doi:10.18632/oncotarget.6530 · Cited by 149
TGF-β and kynurenines as the key to infectious tolerance
Belladonna, M. L., Orabona, C., Grohmann, U., & Puccetti, P. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.11.006 · Cited by 134
Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?
Bilir, C., & Sarısözen, C. (2017) · Journal of Oncological Sciences · doi:10.1016/j.jons.2017.04.001 · Cited by 130
Thomas, S. R., Salahifar, H., Mashima, R., Hunt, N. H., Richardson, D. R., & Stocker, R. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.10.6332 · Cited by 120
Vogel, C. F. A., Wu, D., Goth, S. R., Baek, J., Lollies, A., Domhardt, R., Grindel, A., & Pessah, I. N. (2013) · Immunology and Cell Biology · doi:10.1038/icb.2013.43 · Cited by 117
Hucke, C., MacKenzie, C. R., Adjogble, K. D. Z., Takikawa, O., & Däubener, W. (2004) · Infection and Immunity · doi:10.1128/iai.72.5.2723-2730.2004 · Cited by 110
Post-translational Regulation of Human Indoleamine 2,3-Dioxygenase Activity by Nitric Oxide
Thomas, S. R., Terentis, A. C., Cai, H., Takikawa, O., Levina, A., Lay, P. A., Freewan, M., & Stocker, R. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700669200 · Cited by 105
Shou, D., Wen, L., Song, Z., Yin, J., Sun, Q., & Gong, W. (2016) · Oncotarget · doi:10.18632/oncotarget.11352 · Cited by 101
Blache, C. A., Manuel, E. R., Kaltcheva, T. I., Wong, A. N., Ellenhorn, J. D. I., Blazar, B. R., & Diamond, D. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0193 · Cited by 98
Foy, J., Bertolus, C., Michallet, M., Deneuve, S., Incitti, R., Bendriss‐Vermare, N., Albaret, M. A., Ortiz‐Cuaran, S., Thomas, E., Colombe, A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx210 · Cited by 94
Zaher, S. S., Germain, C., Fu, H., Larkin, F., & George, A. J. T. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-5793 · Cited by 89
Orabona, C., Pallotta, M. T., & Grohmann, U. (2012) · Molecular Medicine · doi:10.2119/molmed.2012.00029 · Cited by 86
Garg, A. D., Vandenberk, L., Woensel, M. V., Belmans, J., Schaaf, M. B. E., Boon, L., Vleeschouwer, S. D., & Agostinis, P. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1295903 · Cited by 77
T-Cell Activation under Hypoxic Conditions Enhances IFN-γ Secretion
Roman, J. A., Rangasamy, T., Guo, J., Sugunan, S., Meednu, N., Packirisamy, G., Shimoda, L. A., Golding, A., Semenza, G. L., & Georas, S. N. (2009) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2008-0139oc · Cited by 75
Qin, Y. W., Ekmekçioglu, S., Forget, M., Székvölgyi, L., Hwu, P., Grimm, E. A., Jazaeri, A. A., & Roszik, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00689 · Cited by 75
Self-citationWANG, D., Saga, Y., Mizukami, H., Sato, N., NONAKA, H., Fujiwara, H., Takei, Y., 町田, 静., Takikawa, O., Ozawa, K., et al. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1295 · Cited by 74
Co‐operative action of interleukin‐10 and interferon‐γ to regulate dendritic cell functions
Yanagawa, Y., Iwabuchi, K., & Onoé, K. (2008) · Immunology · doi:10.1111/j.1365-2567.2008.02986.x · Cited by 73
Jayakumar, H., Ramanathan, P., Jayavelu, S., Dhandapani, H., Ganeshrajah, S., Singh, S. S., & Rajkumar, T. (2016) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2016.04.008 · Cited by 72
Albini, E., Rosini, V., Gargaro, M., Mondanelli, G., Belladonna, M. L., Pallotta, M. T., Volpi, C., Fallarino, F., Macchiarulo, A., Antognelli, C., et al. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12954 · Cited by 70
Nitration and Inactivation of IDO by Peroxynitrite
Fujigaki, H., Saito, K., Lin, F., Fujigaki, S., Takahashi, K., Martin, B. M., Chen, C. Y., Masuda, J., Kowalak, J. A., Takikawa, O., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.372 · Cited by 68
AhR-Mediated, Non-Genomic Modulation of IDO1 Function
Pallotta, M. T., Fallarino, F., Matino, D., Macchiarulo, A., & Orabona, C. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00497 · Cited by 57
Therapeutic gene modified cell based cancer vaccines
Kozłowska, A. K., Mackiewicz, J., & Mackiewicz, A. A. (2013) · Gene · doi:10.1016/j.gene.2013.03.056 · Cited by 52
Herbert, A., Ng, H., Jessup, W., Kockx, M., Cartland, S. P., Thomas, S. R., Hogg, P. J., & Wargon, O. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.10086.x · Cited by 50
Schmidt, S. K., Ebel, S., Keil, E., Woite, C., Ernst, J. F., Benzin, A. E., Rupp, J., & Däubener, W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063301 · Cited by 46
Xin, Y., & Cai, H. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-1024-z · Cited by 44
Gonzalez, Y. I. R., Lynch, P. J., Thompson, E. E., Stultz, B. G., & Hursh, D. A. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.05.017 · Cited by 42
How melanoma cells inactivate NK cells
Pietra, G., Vitale, M., Moretta, L., & Mingari, M. C. (2012) · OncoImmunology · doi:10.4161/onci.20405 · Cited by 38
Prodinger, J., Loacker, L. J., Schmidt, R. L. J., Ratzinger, F., Greiner, G., Witzeneder, N., Hoermann, G., Jutz, S., Pickl, W. F., Steinberger, P., et al. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a0315-135r · Cited by 37
Pallotta, M. T., Orabona, C., Volpi, C., Grohmann, U., Puccetti, P., & Fallarino, F. (2010) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s3971 · Cited by 34
Henrottin, J., Lemaire, C. F., Egrise, D., Zervosen, A., den Eynde, B. J. V., Plenevaux, A., Franci, X., Goldman, S., & Luxen, A. (2016) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2016.03.001 · Cited by 34
Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors
Zulfiqar, B., Mahroo, A., Nasir, K., Farooq, R. K., Jalal, N., Rashid, M. U., & Asghar, K. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s119362 · Cited by 22
Cited by
Antioxidative and Anti-Inflammatory Properties of Cannabidiol
Atalay, S., Jarocka-Karpowicz, I., & Skrzydlewska, E. (2019) · Antioxidants · doi:10.3390/antiox9010021 · Cited by 818
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Labani-Motlagh, A., Ashja-Mahdavi, M., & Loskog, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00940 · Cited by 751
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing
Maynard, A., McCoach, C. E., Rotow, J. K., Harris, L., Haderk, F., Kerr, D. L., Yu, E. A., Schenk, E. L., Tan, W., Zee, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.017 · Cited by 685
Combination strategies to maximize the benefits of cancer immunotherapy
Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01164-5 · Cited by 654
Targeting the IDO1 pathway in cancer: from bench to bedside
Liu, M., Wang, X., Wang, L., Ma, X., Gong, Z., Zhang, S., & Li, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0644-y · Cited by 447
Metadata
- Authors
- Hornyák, L., Dobos, N., Koncz, G., Karányi, Z., Páll, D., Szabó, Z., Halmos, G., & Székvölgyi, L.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-01-31
- Volume
- 9
- Pages
- 151-151
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2792241534
- Cited by
- 311
- References
- 67
- FWCI
- 14.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.